Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.56 |
| ▸ | CDK2 | P24941 | 8/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.49 |
| ▸ | GPR39 | O43194 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PDE1A | P54750 | 2/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.42 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.42 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12954218 | 0.89 | GSK3B (0.72) | GSK3BCDK2CCNA2CCNA1 | |
| SCHEMBL13304838 | 0.88 | GSK3B (0.55) | GSK3BCDK2CCNA2CCNA1GPR39 | |
| SCHEMBL13305604 | 0.86 | GSK3B (0.59) | GSK3BCDK2CCNA2CCNA1GPR39 | |
| SCHEMBL13305689 | 0.84 | GSK3B (0.59) | GSK3BCDK2CCNA2CCNA1GPR39 | |
| SCHEMBL13305409 | 0.83 | GSK3B (0.58) | GSK3BCDK2CCNA2CCNA1GPR39 | |
| SCHEMBL13304765 | 0.83 | CDK2 (0.77) | GSK3BCDK2CCNA2CCNA1GPR39 | |
| SCHEMBL13146486 | 0.82 | CDK2 (0.79) | GSK3BCDK2CCNA2CCNA1 | |
| SCHEMBL13146276 | 0.82 | CDK2 (0.64) | GSK3BCDK2CCNA2CCNA1GPR39 | |
| SCHEMBL14043290 | 0.81 | GSK3B (0.60) | GSK3BCDK2CCNA2CCNA1GPR39 | |
| SCHEMBL13304785 | 0.80 | CDK2 (0.61) | GSK3BCDK2CCNA2CCNA1GPR39 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |